Brendan Haberle’s practice focuses on technology transactions, primarily within the life sciences industry.
Mr. Haberle advises companies on technology licensing and intellectual property portfolio management, as well as regarding intellectual property concerns within corporate transactions such as public offerings and mergers and acquisitions.
Mr. Haberle also has experience representing startup and emerging growth companies in many industries on early stage matters such as formation, fund raising, and corporate governance.
Prior to joining the firm, Mr. Haberle supported the Intelligence Community’s counter-proliferation and counter-terrorism missions, deploying to Iraq and Afghanistan.
While in law school, Mr. Haberle served on the Arizona Law Review and as Co-President of the Arizona Intellectual Property and Cyberlaw Society.
Mr. Haberle’s recent transactions include:
- Ignyta, Inc. in its US$1.7 billion merger with Roche
- Impact Biomedicines in its acquisition by Celgene for up to